Multiple myeloma: trials for referral

Where the open trials are

Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.

Registry facts, one per line, newest first.

• 5 Nov 2026

  New in the registry

  A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.

  2024-519498-20-00 · Phase 1/2 · Spain

  Source: EU CTIS
• 9 Oct 2026

  Phase changed: Phase 2 → Phase 1/2

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787 · Phase 1/2 · France

  Source: ClinicalTrials.gov
• 26 Jun 2026

  Status changed: Recruiting → Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287 · Phase 3 · Germany

  Source: ClinicalTrials.gov
• 11 Aug 2026

  Status changed: Recruiting → Not yet recruiting

  Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.

  NCT07757412 · Phase 2 · Denmark, Estonia, Finland, Norway

  Source: ClinicalTrials.gov
• 5 Nov 2026

  Phase changed: Phase 1 → Phase 1/2

  A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT07455851 · Phase 1/2 · Australia, Greece

  Source: ClinicalTrials.gov
• 19 Oct 2026

  Opened for recruitment

  A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  NCT07095452 · Phase 2/3 · Spain, France, Japan, Norway, United States

  Source: ClinicalTrials.gov
• 12 May 2026

  Phase changed: Phase 1/2 → Phase 1

  Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06896916 · Phase 1 · Australia, Canada, France, Japan, Netherlands, Norway

  Source: ClinicalTrials.gov
• 22 Apr 2026

  Opened for recruitment

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 27 Mar 2026

  Closed for recruitment

  Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06223516 · Phase 1 · Germany, France, Israel, Japan, United States

  Source: ClinicalTrials.gov
• 17 Aug 2026

  Status changed: Completed → Running, not recruiting

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158 · Phase 3 · Austria, Germany

  Source: ClinicalTrials.gov
• 14 May 2024

  Status changed: Recruiting → Not yet recruiting

  Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

  NCT05982275 · Phase 1/2 · Spain

  Source: ClinicalTrials.gov
• 1 Jul 2026

  Phase changed: Phase 3 → Phase 4

  Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  NCT06057402 · Phase 4 · Australia, Canada, China, Germany, Spain, France

  Source: ClinicalTrials.gov
• 13 May 2026

  Phase changed: Phase 2 → Phase 1/2

  A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  NCT05828511 · Phase 1/2 · Spain, France, United States

  Source: ClinicalTrials.gov
• 17 Sept 2026

  Closed for recruitment

  A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

  NCT05827016 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 7 Oct 2026

  Opened for recruitment

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036 · Phase 3 · Australia, Belgium, Brazil, Canada, Chile, Germany

  Source: ClinicalTrials.gov
• 5 Nov 2026

  Status changed: Completed → Running, not recruiting

  A Rollover Study of CC-122

  NCT05688475 · Phase 1 · France, Japan, Netherlands, United States

  Source: ClinicalTrials.gov
• 13 Jul 2026

  Opened for recruitment

  A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT05650632 · Phase 1 · Canada, Denmark, Spain, France, United Kingdom, Israel

  Source: ClinicalTrials.gov
• 11 Dec 2024

  Opened for recruitment

  Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

  NCT05665140 · Phase 2/3 · Germany

  Source: ClinicalTrials.gov
• 11 Dec 2024

  Phase changed: Phase 2 → Phase 2/3

  Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

  NCT05665140 · Phase 2/3 · Germany

  Source: ClinicalTrials.gov
• 5 Sept 2025

  Opened for recruitment

  A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05372354 · Phase 1/2 · Canada, Spain, United Kingdom, Norway, United States

  Source: ClinicalTrials.gov
• 7 Oct 2026

  Opened for recruitment

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 17 Mar 2026

  Closed for recruitment

  A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05257083 · Phase 3 · Australia, Belgium, Canada, Switzerland, Czechia, Germany

  Source: ClinicalTrials.gov
• 7 Nov 2024

  Closed for recruitment

  MInimal Residual Disease Adapted Strategy

  NCT04934475 · Phase 3 · Belgium, France, Réunion

  Source: ClinicalTrials.gov
• 24 Aug 2026

  Opened for recruitment

  A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  NCT05020236 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 20 Mar 2025

  Status changed: Running, not recruiting → Completed

  REST - Replacing Steroids in the Transplant Ineligble

  NCT04939844 · Phase 2 · Denmark, Norway

  Source: ClinicalTrials.gov
• 15 Jun 2026

  Closed for recruitment

  A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

  NCT04998786 · Phase 2 · France

  Source: ClinicalTrials.gov
• 5 Mar 2026

  Status changed: Completed → Running, not recruiting

  Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

  NCT04802356 · Phase 2 · Spain

  Source: ClinicalTrials.gov
• 20 Oct 2026

  Opened for recruitment

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04910568 · Phase 1 · Australia, Canada, Czechia, Denmark, Spain, France

  Source: ClinicalTrials.gov
• 13 Apr 2026

  Status changed: Completed → Running, not recruiting

  CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

  NCT04667663 · Phase 1 · Ireland

  Source: ClinicalTrials.gov
• 20 Mar 2025

  Opened for recruitment

  The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

  NCT04513639 · Phase 2/3 · Lithuania, Norway

  Source: ClinicalTrials.gov
• 17 Oct 2023

  Opened for recruitment

  FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)

  NCT04349358 · Phase 2 · France

  Source: ClinicalTrials.gov
• 5 Dec 2025

  Status changed: Completed → Running, not recruiting

  Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

  NCT04184050 · Phase 1 · Spain, France, United States

  Source: ClinicalTrials.gov
• 6 Feb 2026

  Phase changed: Phase 1 → Phase 1/2

  A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03933735 · Phase 1/2 · Germany, United States

  Source: ClinicalTrials.gov
• 14 Aug 2025

  Phase changed: Phase 1/2 → Phase 2

  A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03314181 · Phase 2 · Australia, Canada, Germany, Denmark, France, Japan

  Source: ClinicalTrials.gov
• 30 Sept 2025

  Closed for recruitment

  Iceland Screens, Treats or Prevents Multiple Myeloma

  NCT03327597 · Phase 2 · Iceland

  Source: ClinicalTrials.gov
• 15 May 2026

  Status changed: Completed → Running, not recruiting

  Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

  NCT03104842 · Phase 2 · Germany

  Source: ClinicalTrials.gov
• 8 Aug 2025

  Status changed: Completed → Running, not recruiting

  Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

  NCT03314636 · Phase 2 · Denmark, Norway, Sweden

  Source: ClinicalTrials.gov
• 23 Dec 2025

  Closed for recruitment

  Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

  NCT05665140 · Phase 2/3 · Germany

  Source: ClinicalTrials.gov
• 25 Sept 2026

  Closed for recruitment

  A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT05650632 · Phase 1 · Canada, Denmark, Spain, France, United Kingdom, Israel

  Source: ClinicalTrials.gov
• 21 Sept 2026

  Opened for recruitment

  A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

  NCT05827016 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 29 Jun 2026

  Closed for recruitment

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036 · Phase 3 · Australia, Belgium, Brazil, Canada, Chile, Germany

  Source: ClinicalTrials.gov
• 10 Sept 2026

  Opened for recruitment

  A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05257083 · Phase 3 · Australia, Belgium, Canada, Switzerland, Czechia, Germany

  Source: ClinicalTrials.gov
• 27 Apr 2026

  Opened for recruitment

  Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

  NCT05982275 · Phase 1/2 · Spain

  Source: ClinicalTrials.gov
• 30 Sept 2026

  Opened for recruitment

  Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06223516 · Phase 1 · Germany, France, Israel, Japan, United States

  Source: ClinicalTrials.gov
• 28 Oct 2026

  Closed for recruitment

  A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05372354 · Phase 1/2 · Canada, Spain, United Kingdom, Norway, United States

  Source: ClinicalTrials.gov
• 5 Jun 2026

  Closed for recruitment

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 23 Aug 2024

  Closed for recruitment

  FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)

  NCT04349358 · Phase 2 · France

  Source: ClinicalTrials.gov
• 19 Aug 2026

  Closed for recruitment

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04910568 · Phase 1 · Australia, Canada, Czechia, Denmark, Spain, France

  Source: ClinicalTrials.gov
• 28 Aug 2026

  Closed for recruitment

  A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  NCT05020236 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 10 Jun 2026

  Closed for recruitment

  The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

  NCT04513639 · Phase 2/3 · Lithuania, Norway

  Source: ClinicalTrials.gov
• 10 Jun 2026

  Status changed: Running, not recruiting → Not yet recruiting

  A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

  NCT04998786 · Phase 2 · France

  Source: ClinicalTrials.gov
• 5 Oct 2026

  Status changed: Running, not recruiting → Not yet recruiting

  MInimal Residual Disease Adapted Strategy

  NCT04934475 · Phase 3 · Belgium, France, Réunion

  Source: ClinicalTrials.gov
• 22 Apr 2026

  Status changed: Running, not recruiting → Not yet recruiting

  Iceland Screens, Treats or Prevents Multiple Myeloma

  NCT03327597 · Phase 2 · Iceland

  Source: ClinicalTrials.gov
• 23 Oct 2026

  Closed for recruitment

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

  Source: ClinicalTrials.gov
• 16 Apr 2026

  Closed for recruitment

  A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  NCT07095452 · Phase 2/3 · Spain, France, Japan, Norway, United States

  Source: ClinicalTrials.gov
• 30 Oct 2026

  Opened for recruitment

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287 · Phase 3 · Germany

  Source: ClinicalTrials.gov
• 26 Aug 2026

  Opened for recruitment

  Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.

  NCT07757412 · Phase 2 · Denmark, Estonia, Finland, Norway

  Source: ClinicalTrials.gov
• 4 Nov 2026

  Opened for recruitment

  BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

  NCT07009899 · Phase 2 · United States

  Source: ClinicalTrials.gov
• 4 Nov 2026

  Stopped early

  Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma

  NCT05996367 · No phase · Brazil

  Source: ClinicalTrials.gov
• 4 Nov 2026

  Opened for recruitment

  FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

  NCT07221032 · Phase 1 · United States

  Source: ClinicalTrials.gov
• 17 Oct 2023

  Phase changed: No phase → Phase 2

  FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)

  NCT04349358 · Phase 2 · France

  Source: ClinicalTrials.gov
• 30 Apr 2026

  Phase changed: No phase → Phase 2

  Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

  NCT05889221 · Phase 2 · France

  Source: ClinicalTrials.gov
• 30 Sept 2025

  Phase changed: No phase → Phase 2

  Iceland Screens, Treats or Prevents Multiple Myeloma

  NCT03327597 · Phase 2 · Iceland

  Source: ClinicalTrials.gov
• 3 Nov 2026

  Closed for recruitment

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584 · No phase · Austria, Belgium, Switzerland, Germany, Spain, France

  Source: ClinicalTrials.gov
• 3 Nov 2026

  Opened for recruitment

  Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

  NCT06323447 · No phase · Spain, United States

  Source: ClinicalTrials.gov
• 3 Nov 2026

  New in the registry

  The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial

  NCT07912684 · No phase · Italy

  Source: ClinicalTrials.gov
• 3 Nov 2026

  New in the registry

  Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers

  NCT07914556 · Phase 1 · China

  Source: ClinicalTrials.gov

Results card

Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.

• Phase 2Ended 12 Oct 2026

  Completed100 participants

  2023-505053-40-00

  Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD

  Registry record

• Phase 1Ended 6 Oct 2026

  Completed20 participants

  NCT03070327

  BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

  Registry record

• Phase 1Ended 4 Sept 2026

  Completed8 participants

  NCT07444268

  How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

  Registry record

• No phaseEnded 1 Sept 2026

  Completed59 participants

  NCT07088783

  The Effect of Mobile Application-Based Education Developed According to Orem's Self-Care Model in Multiple Myeloma Patients

  Registry record

• Phase 2Ended 30 Aug 2026

  Completed29 participants

  NCT05900882

  SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

  • Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. · Blood advances, 2026
  Registry record

• Phase 3Ended 28 Aug 2026

  Completed294 participants

  NCT03993912

  Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

  Registry record

• Phase 2Ended 25 Aug 2026

  Completed187 participants

  NCT04649359

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  • Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. · Clinical pharmacokinetics, 2026
  • Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma. · Clinical lymphoma, myeloma & leukemia, 2026
  • Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies. · Future oncology (London, England), 2026
  Registry record

• No phaseEnded 14 Aug 2026

  Completed70 participants

  NCT07882069

  Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia

  Registry record

• No phaseEnded 24 Jul 2026

  Completed40 participants

  NCT03389347

  High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

  Registry record

• Phase 1Ended 1 Jul 2026

  Completed7 participants

  NCT05139225

  A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

  Registry record

• Phase 1Ended 16 Jun 2026

  Completed3 participants

  NCT06203912

  Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

  Registry record

• No phaseEnded 1 Jun 2026

  Completed549 participants

  NCT06483139

  Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

  Registry record

• No phaseEnded 31 May 2026

  Completed121 participants

  NCT05742217

  A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases

  Registry record

• Phase 2Ended 27 May 2026

  Completed20 participants

  NCT04052880

  Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

  Registry record

• Phase 1/2Ended 22 May 2026

  Completed41 participants

  2022-500782-27-00

  A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)

  Registry record

• Phase 3Ended 4 May 2026

  Completed390 participants

  NCT03301220

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  • Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma. · Japanese journal of clinical oncology, 2026
  Registry record

• Phase 3Ended 4 May 2026

  Completed200 participants

  NCT03901963

  A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  Registry record

• Phase 1Ended 23 Apr 2026

  Completed35 participants

  NCT03602612

  T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

  • Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment. · Journal for immunotherapy of cancer, 2026
  Registry record

• Phase 3Ended 21 Apr 2026

  Completed395 participants

  NCT03652064

  A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  • Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. · Blood advances, 2026
  • Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026
  Registry record

• Phase 1/2Ended 13 Apr 2026

  Completed40 participants

  NCT04696809

  A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

  • Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort. · Cancer, 2026
  Registry record

• Phase 3Ended 13 Apr 2026

  Completed386 participants

  NCT03651128

  Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

  • Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. · Advances in therapy, 2026
  Registry record

• No phaseEnded 9 Apr 2026

  Completed100 participants

  NCT06338150

  Precision Medicine Study

  Registry record

• Phase 1Ended 1 Apr 2026

  Completed94 participants

  NCT04354246

  COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

  Registry record

• Phase 2Ended 30 Mar 2026

  Completed477 participants

  NCT02203643

  Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

  Registry record

• Phase 2Ended 30 Mar 2026

  Completed76 participants

  NCT01816971

  Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

  Registry record

• Phase 1Ended 25 Mar 2026

  Completed50 participants

  NCT03984097

  A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

  Registry record

• Phase 2Ended 24 Mar 2026

  Completed270 participants

  NCT01810588

  Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

  Registry record

• No phaseEnded 23 Mar 2026

  Completed20 participants

  NCT06418750

  Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study

  Registry record

• Phase 2Ended 19 Mar 2026

  Completed74 participants

  NCT01559935

  Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

  Registry record

• Phase 1Ended 17 Mar 2026

  Completed225 participants

  NCT04557150

  A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

  • Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma. · Clinical pharmacology and therapeutics, 2026
  Registry record

• Phase 2Ended 16 Mar 2026

  Completed33 participants

  NCT04151667

  Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

  Registry record

• Phase 1/2Ended 2 Mar 2026

  Completed12 participants

  2024-516969-36-00

  A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

  Registry record

• Phase 1Ended 2 Mar 2026

  Completed27 participants

  NCT05024045

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  Registry record

• No phaseEnded 1 Mar 2026

  Completed9 participants

  NCT05620238

  Home Treatment With Carfilzomib in Patients With Multiple Myeloma

  Registry record

• Phase 2Ended 23 Feb 2026

  Completed67 participants

  NCT02719613

  Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

  Registry record

• No phaseEnded 23 Feb 2026

  Completed583 participants

  NCT04458831

  A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

  Registry record

• No phaseEnded 13 Feb 2026

  Completed482 participants

  NCT04328662

  A Study of Ninlaro in Real World Clinical Practice in China

  Registry record

• Phase 2Ended 10 Feb 2026

  Completed177 participants

  NCT05064358

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  Registry record

• Phase 3Ended 30 Jan 2026

  Completed514 participants

  NCT05804032

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  Registry record

• Phase 2Ended 20 Jan 2026

  Completed20 participants

  NCT04975555

  Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

  Registry record

• Phase 1Ended 20 Jan 2026

  Completed18 participants

  2024-517381-42-00

  Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM

  Registry record

• No phaseEnded 15 Jan 2026

  Completed20 participants

  NCT06549634

  Biomarkers of AKI in Patients Receiving Daratumumab

  Registry record

• Phase 2Ended 15 Jan 2026

  Completed312 participants

  NCT03601078

  An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

  Registry record

• No phaseEnded 14 Jan 2026

  Completed911 participants

  NCT03106324

  A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

  Registry record

• Phase 1Ended 7 Jan 2026

  Completed355 participants

  NCT03275103

  Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

  • FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. · Nature medicine, 2026
  Registry record

• Phase 2Ended 5 Jan 2026

  Completed20 participants

  NCT04205409

  Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

  Registry record

• Phase 2Ended Dec 2025

  Completed35 participants

  NCT01067287

  Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

  Registry record

• No phaseEnded 31 Dec 2025

  Completed100 participants

  NCT07611812

  Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review

  Registry record

• Phase 1Ended 31 Dec 2025

  Completed83 participants

  NCT02332850

  Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

  Registry record

• No phaseEnded 31 Dec 2025

  Completed408 participants

  NCT06472778

  A Real-world Study in Participants With Smoldering Multiple Myeloma

  Registry record

• No phaseEnded 29 Dec 2025

  Completed46 participants

  NCT04364256

  Muscle Stimulation for Physical Function During Stem Cell Transplant

  Registry record

• Phase 1Ended 22 Dec 2025

  Completed130 participants

  NCT04674813

  A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma. · Blood, 2026
  Registry record

• No phaseEnded 15 Dec 2025

  Completed36 participants

  NCT05625971

  Non-invasive MRD Assessment in Multiple Myeloma

  Registry record

• Phase 2Ended 12 Dec 2025

  Completed86 participants

  NCT05014412

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  • Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. · Clinical pharmacokinetics, 2026
  Registry record

• Early Phase 1Ended 10 Dec 2025

  Completed30 participants

  NCT03631043

  Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

  Registry record

• Phase 2Ended 8 Dec 2025

  Completed43 participants

  NCT03159702

  Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

  Registry record

• Phase 2Ended 1 Dec 2025

  Completed46 participants

  NCT02969837

  Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

  Registry record

• Phase 2Ended 26 Nov 2025

  Completed274 participants

  2024-518400-50-00

  Clinical Trial conduct to investigate if Daratumumab therapy for multiple myeloma patients with minimal residual disease (MRD) reappearance or biochemical relapse is effective in preventive therapy.

  Registry record

• No phaseEnded 26 Nov 2025

  Completed212 participants

  NCT07457112

  EHealth Educational Intervention to Improve Self-Management and Coping Behaviors Among Cancer Patients

  Registry record

• Phase 1Ended 19 Nov 2025

  Completed22 participants

  NCT04640779

  Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

  Registry record

Not medical advice. fetched 6 Nov 2026